Working… Menu

Measuring the Effects of Continuous Dopaminergic Stimulation on Nocturnal Movements in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01554306
Recruitment Status : Terminated (difficulty to include enough subjects)
First Posted : March 14, 2012
Last Update Posted : October 31, 2016
Information provided by (Responsible Party):
D.A.A. Pevernagie, MD PhD, Sleep Medicine Centre Kempenhaeghe

Brief Summary:

Parkinson's disease (PD) is a neurodegenerative disorder that is characterized with motor symptoms such as hypokinesia, rigidity, tremor and postural instability. These symptoms can also be present during the night. Half of the patients with PD have difficulty turning around in bed. This nocturnal hypokinesia is considered as a possible cause of sleep problems in this population. The diagnosis nocturnal hypokinesia is based on the clinical interview. There is a need for a diagnostic devices that measures nocturnal movements, preferably in the home setting. This device can be used in the diagnostic trajectory as well in the evaluation of treatment. Recently the Dynaport Minimod (McRoberts, The Hague) has been developed to register nocturnal movements. The tri-axial accelerometer has been developed to measure position changes in the night. A validation study with actigraphy and polysomnography concluded that the Dynaport MiniMod is a valid an feasible device for assessing intensity and physical activity and changes of body position during sleep.

Nocturnal hypokinesia is treated with nocturnal dopamine. Sometimes a night-time dose of dopaminergics is adequate, but most of the time slow release dopaminergics are needed. However response fluctuations can negatively influence the treatment. In these cases continuous dopaminergic stimulation is needed, such as rotigotine. Rotigotine treats response fluctuations during the day and studies show that sleep quality measured with questionnaires improves. If the improvement of sleep quality is caused by improved bed mobility has not been studied yet. The study hypothesis is that rotigotine does not influence nocturnal hypokinesia in PD.

Objective of the study:


• To study the effect of rotigotine on nocturnal hypokinesia


  • To study the possibility of measuring nocturnal hypokinesia and its severity in a home setting
  • To correlate improvements in sleep quality by rotigotine with changes in nocturnal hypokinesia

Study design:

We will study patients who will recieve rotigotine as a part of their usual care. During three nights, nocturnal movements are being registered with movement sensors, before treatment has started as well as after a stable medication dose of one month. We will also assess sleep quality with questionnaires.

Study population:

The study population are patients with Parkinson's disease with sleep problems caused by nocturnal hypokinesia, who will start treatment with rotigotine. Patients will be recruited in the neurology patient outdoor clinic of the Radboud University Medical Centre Nijmegen. We will ask the treating neurologist to inform us when a patient will start treatment with rotigotine. One of the researchers will contact the patient to give further information about the study. The study is a first hypothesis generating study and we will start with the inclusion of 10 patients.

Intervention (if applicable):

Primary study parameters/outcome of the study:

Position changes over the night.

Secundary study parameters/outcome of the study (if applicable):


  • Degree of mobility, measured as the speed of the movements
  • Total amount of movements
  • Score on the motor symptom scale according to the MDS-UPDRS part III


  • Nocturnal sleep quality Excessive daytime sleepiness
  • Presence of nocturnal akinesia

Condition or disease
Nocturnal Hypokinesia Parkinsons's Disease Rotigotine

Layout table for study information
Study Type : Observational
Actual Enrollment : 2 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Observational Study on the Effecst of Continuous Dopaminergic Stimulation on Nocturnal Hypokinesia in Parkinson's Disease
Study Start Date : March 2012
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

parkinson's disease, nocturnal hypokinesia, rotigotine

Primary Outcome Measures :
  1. Position changes over the night. [ Time Frame: max 1 year ]

Secondary Outcome Measures :
  1. • Degree of mobility, measured as the speed of the movements [ Time Frame: Max 1 year ]
  2. • Total amount of movements [ Time Frame: Max 1 year ]
  3. • Score on the motor symptom scale according to the MDS-UPDRS part III [ Time Frame: Max 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Parkinson's disease with nocturnal hypokinesia based on the clinical interview who are going to start with rotigotine

Inclusion Criteria:

  • Patients with idiopathic PD (defined by UK Brain Bank criteria)
  • Patients who will start treatment with rotigotine
  • Hoehn & Yahr stage II - IV
  • Subjective sleep problems most likely caused by nocturnal hypokinesia, based on clinical interview

Exclusion Criteria:

  • Other significant causes for nocturnal motor symptoms which are not dopamine-responsive
  • Previous surgery for PD
  • Mini- mental state examination score < 25
  • Concurrent hallucination or psychosis
  • History of skin hypersensitivity to adhesives or other transdermals

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01554306

Layout table for location information
Sleep Medicine Centre Kempenhaeghe
Heeze, Netherlands, 5591 VE
Sponsors and Collaborators
Sleep Medicine Centre Kempenhaeghe
Layout table for investigator information
Study Director: Dirk AA Pevernagie, MD PhD Sleep Medicine Centre Kempenhaeghe

Layout table for additonal information
Responsible Party: D.A.A. Pevernagie, MD PhD, MD PhD, Sleep Medicine Centre Kempenhaeghe Identifier: NCT01554306     History of Changes
Other Study ID Numbers: 38851.091.11
First Posted: March 14, 2012    Key Record Dates
Last Update Posted: October 31, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Dopamine Agonists
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents